stockrow
Friday 6 November 2026
Export TOVX’s income statement to Excel — free account
Theriva Biologics, Inc.
TOVX Healthcare Biotechnology
- EPS
- +96.4%
- Free cash flow
- +34.7%
- Total debt
- −1.16%
Quarter to June 2026, against a year earlier
0.17
0.00
0.00%
Follow TOVX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | 3 | — | 0 | 0 | 0 | 0.0% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (28) | (15) | (13) | (15) | (10) | (14) | (21) | (20) | (26) | (24) | (12) | (1.7%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (28) | (15) | (13) | (15) | (10) | (14) | (20) | (18) | (26) | (24) | (12) | (1.7%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (2,534.96) | (1,573.43) | (1,015.00) | (245.00) | (165.00) | (47.50) | (32.75) | (28.50) | (19.03) | (2.08) | (0.69) | (54.6%) | ||||||
| Cash flow | (2,583.43) | (1,422.82) | (693.94) | (210.84) | (160.11) | (26.44) | (31.12) | (29.48) | (12.56) | (1.37) | (0.28) | (56.7%) | ||||||
| Capex | (52.69) | (14.93) | (0.28) | 0.00 | (0.12) | (0.03) | (0.19) | (0.31) | 0.00 | 0.00 | 0.00 | (66.4%) | ||||||
| Free cash flow | (2,636.11) | (1,437.75) | (694.22) | (210.84) | (160.22) | (26.47) | (31.31) | (29.80) | (12.56) | (1.38) | (0.28) | (56.8%) | ||||||
| Book value | 208.24 | (240.14) | 568.63 | (16.06) | (99.21) | 134.17 | 84.54 | 57.37 | 14.14 | 1.27 | 0.27 | (43.3%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 12 | 31 | +118.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (28) | (20) | (17) | (14) | (12) | (13) | (19) | (19) | (17) | (17) | (13) | (5.6%) | |||||
| Capex | (1) | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (26.6%) | ||||||
| Free cash flow | (28) | (20) | (17) | (14) | (12) | (13) | (19) | (19) | (17) | (17) | (13) | (5.8%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 2 | 8 | 26 | 11 | 5 | 65 | 38 | 21 | 9 | 7 | 2 | +17.0% | |||||
| Net debt | (19) | (17) | (29) | (15) | (6) | (66) | (42) | (23) | (12) | (11) | (10) | (5.6%) | ||||||
| Shareholders’ equity | 2 | (3) | 14 | (1) | (8) | 65 | 52 | 37 | 19 | 15 | 12 | +23.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (102.19) | (107.10) | (103.27) | (67.87) | (97.93) | (58.87) | (28.16) | (28.88) | (56.65) | (68.62) | (37.14) | +33.6 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (131.40) | (96.03) | (218.10) | (375.98) | (301.72) | (376.0) pt | ||||||
| ROE | (315.96) | 3,813.26 | (1,013.87) | (1,245.72) | 158.60 | (83.73) | (34.16) | (41.33) | (91.57) | (146.58) | (115.11) | +169.4 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 30 | 25 | 13 | 11 | 10 | 9 | 9 | 22 | 22 | 16 | — | (6.7%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2010 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026
Theriva Biologics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ACTU Actuate Therapeutics, Inc. | $18.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| ICU SeaStar Medical Holding Corporation | $10.2M | — (loss-making) | — (loss-making) | +81.95% (above 0%: growing) | n/m | +0.43% (above 0%: growing) | 91.22% | (616.42%) | Compare |
| MBRX Moleculin Biotech, Inc. | $9.2M | 0.0× | — | — | n/m | −19.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.1M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LEXX Lexaria Bioscience Corp. | $8.8M | — (loss-making) | — (loss-making) | −89.12% (below 0%: shrinking) | n/m | +53.90% (above 0%: growing) | 100.00% | 0.00% | Compare |
| NKGN NKGen Biotech, Inc. | $8.8M | — (loss-making) | — | — | n/m | +28.68% (above 0%: growing) | 100.00% | 0.00% | Compare |
| LTRN Lantern Pharma Inc. | $7.9M | — (loss-making) | — | — | n/m | +25.31% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TOVX Theriva Biologics, Inc. | $7.7M | — (loss-making) | — | +33.08% (above 0%: growing) | n/m | +34.69% (above 0%: growing) | 100.00% | 0.00% | |
| MTVA MetaVia Inc. | $7.2M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $8.9M | — | — | — | — | +12.87% | 45.61% | 0.00% |
Pay and ownership Proxy statement filed 20 October 2026
Ownership
Directors and executive officers, together
1.33%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement